News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
16,764 Results
Type
Article (910)
Company Profile (3)
Press Release (15851)
Section
Business (3642)
Career Advice (5)
Deals (533)
Drug Development (5320)
Employer Resources (1)
FDA (499)
Job Trends (706)
News (9499)
Policy (726)
Tag
Academia (43)
Accelerated approval (1)
Adcomms (1)
Allergies (2)
Alliances (1080)
ALS (1)
Alzheimer's disease (52)
Antibody-drug conjugate (ADC) (22)
Approvals (525)
Artificial intelligence (4)
Best Places to Work (744)
Biosimilars (7)
Biotechnology (3)
Bladder cancer (14)
Brain cancer (5)
Breast cancer (64)
Cancer (434)
Cardiovascular disease (1)
Career advice (5)
CAR-T (8)
Cell therapy (26)
Cervical cancer (8)
Clinical research (4714)
Collaboration (32)
COVID-19 (64)
C-suite (6)
Data (194)
Diabetes (3)
Diagnostics (50)
Digital health (2)
Drug discovery (2)
Earnings (1670)
Employer resources (1)
Events (2862)
Executive appointments (14)
FDA (573)
Frontotemporal dementia (1)
Funding (15)
GLP-1 (13)
Government (90)
Grass and pollen (1)
Guidances (6)
Healthcare (380)
Immunology and inflammation (2)
Indications (8)
Infectious disease (70)
Inflammatory bowel disease (5)
Influenza (4)
Intellectual property (5)
Interviews (1)
IPO (340)
Job creations (18)
Job search strategy (3)
Kidney cancer (1)
Layoffs (4)
Legal (44)
Liver cancer (22)
Lung cancer (91)
Lymphoma (29)
Manufacturing (6)
MASH (2)
Medical device (194)
Medtech (194)
Mergers & acquisitions (202)
Metabolic disorders (6)
Neurodegenerative disease (3)
Neuropsychiatric disorders (1)
Neuroscience (57)
NextGen: Class of 2025 (127)
Non-profit (50)
Obesity (1)
Opinion (2)
Ovarian cancer (20)
Pain (1)
Pancreatic cancer (26)
Parkinson's disease (6)
Patents (6)
Patient recruitment (9)
Peanut (1)
People (874)
Phase I (1246)
Phase II (2005)
Phase III (2116)
Pipeline (76)
Postmarket research (78)
Preclinical (354)
Prostate cancer (17)
Radiopharmaceuticals (9)
Rare diseases (6)
Real estate (39)
Recruiting (1)
Regulatory (736)
Research institute (50)
Resumes & cover letters (2)
RSV (3)
Series A (2)
Startups (51)
Stomach cancer (2)
Supply chain (2)
Vaccines (23)
Weight loss (1)
Date
Today (7)
Last 7 days (39)
Last 30 days (115)
Last 365 days (1433)
2025 (459)
2024 (1477)
2023 (1592)
2022 (1751)
2021 (1746)
2020 (1568)
2019 (1317)
2018 (1056)
2017 (949)
2016 (863)
2015 (918)
2014 (611)
2013 (449)
2012 (336)
2011 (346)
2010 (240)
Location
Africa (9)
Arizona (1)
Asia (1398)
Australia (339)
California (222)
Canada (95)
China (58)
Colorado (19)
Connecticut (11)
Delaware (25)
Europe (3608)
Florida (18)
Illinois (15)
Indiana (14)
Japan (19)
Kansas (1)
Kentucky (2)
Maine (1)
Maryland (26)
Massachusetts (137)
Minnesota (9)
Montana (9)
Nevada (6)
New Jersey (125)
New York (110)
North Carolina (18)
Northern California (89)
Ohio (2)
Oklahoma (1)
Pennsylvania (36)
South America (11)
Southern California (95)
Texas (28)
United States (844)
Utah (15)
Virginia (2)
Washington State (15)
16,764 Results for "ose immunotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
April 23, 2025
·
5 min read
Press Releases
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
May 5, 2025
·
8 min read
Press Releases
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
April 9, 2025
·
4 min read
Press Releases
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
April 3, 2025
·
6 min read
Press Releases
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
March 26, 2025
·
17 min read
Press Releases
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
March 7, 2025
·
3 min read
Press Releases
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
March 11, 2025
·
7 min read
Business
OSE Immunotherapeutics Provides Business and Corporate Update
OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.
May 30, 2024
·
12 min read
Press Releases
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
January 14, 2025
·
5 min read
Press Releases
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
December 3, 2024
·
8 min read
1 of 1,677
Next
